Podcasts about editor in chief dr

In this debut episode of JACC This Week with Editor-in-Chief Dr. Harlan Krumholz, we explore groundbreaking studies and timely insights from the July 1st issue. Highlights include the impact of wildfire smoke on heart failure risk, new hemodynamic data on mechanical circulatory support in cardiogenic shock, and sobering cardiovascular mortality trends over the past 25 years. Plus, updates on aspirin use, cognitive impairment in CVD, ACC/AHA performance measures, and a leadership reflection from ACC President Dr. Christopher Kramer.

In this JACC Deep Dive episode, Editor-in-Chief Dr. Harlan Krumholz discusses a major study on sudden cardiac arrest in young competitive athletes, highlighting survival rates, causes, and racial disparities. The study shows that survival improves dramatically with immediate AED use and has increased over time, emphasizing the need for widespread emergency preparedness and health equity efforts.. While progress has been made, ensuring universal access to CPR training and AEDs remains critical to saving lives.

In this episode of The Future Conceived, the official podcast of the Society for the Study of Reproduction (SSR), host Dr. Pam Monahan welcomes the editorial team from Biology of Reproduction (BOR), the flagship journal of SSR. Listen in as BOR's Editor-in-Chief Dr. Romana Nowak, Editor-in-Chief Dr. Mary Zelinski, and Publications Manager Ms. Jenny Kimball discuss exciting new features and updates at BOR. This insightful conversation provides a run-through of the academic peer-review publishing process and the structure of scientific journals. Discover the benefits of publishing in and reading BOR, learn about its newly expanded scope and categories, and get a sneak peek at upcoming special issues. The editorial team also shares ways for the reproductive science community to get involved with BOR, including becoming a peer reviewer or joining committees. This episode is a must-listen for anyone interested in reproductive research and the valuable resources offered by BOR and SSR, including the benefit of free publication for SSR members.

Editor in Chief Dr. Sue Yom hosts a discussion on the role of radiation for gallbladder cancer, as it is managed in India versus the U.S. Guests are Section Editor Dr. Michael Chuong, Vice Chair and Medical Director of Radiation Oncology at Miami Cancer Institute, and Dr. Sushma Agrawal, Professor from the Department of Radiotherapy at Sanjay Gandhi Post Graduate Institute of Medical Sciences in Lacknow, India, RACE-GB Principal Investigator, and first author of the primary trial report, A Randomized Study of Consolidation Chemoradiotherapy Versus Observation After First-line Chemotherapy in Advanced Gallbladder Cancers: RACE-GB Study.

Dr. Julia Ann Koretski, a psychiatrist and Digital Editor of the Journal of Clinical Psychopharmacology (JCP), leads a conversation about the guest editorial “Ethics in Psychedelic Science: Promises and Responsibilities” with its author, Dominic Sisti, PhD, a medical ethicist from the Perelman School of Medicine at the University of Pennsylvania, and a JCP podcast panel of Editor-in-Chief Dr. Anthony Rothschild and Associate Editor Dr. Richard Balon. Dr. Sisti provides an overview of recent regulatory actions in this area and summarizes the history of “utopian hype” in the field. The editorial and the podcast discussion detail what elements are required to build a solid ethics infrastructure for psychedelics research and clinical delivery that is free of hype and bias. Sisti advises moving ahead with caution, while noting that “the range of potentially treatable conditions is wide—including PTSD, major depression, anxiety disorder, obsessive compulsive disorder, anorexia nervosa, and substance use disorders.” The guest editorial is published in the January-February 2025 issue of JCP.

Dr. Julia Ann Koretski, a psychiatrist and Digital Editor of the Journal of Clinical Psychopharmacology (JCP), leads a conversation about the guest editorial “Ethics in Psychedelic Science: Promises and Responsibilities” with its author, Dominic Sisti, PhD, a medical ethicist from the Perelman School of Medicine at the University of Pennsylvania, and a JCP podcast panel of Editor-in-Chief Dr. Anthony Rothschild and Associate Editor Dr. Richard Balon. Dr. Sisti provides an overview of recent regulatory actions in this area and summarizes the history of “utopian hype” in the field. The editorial and the podcast discussion detail what elements are required to build a solid ethics infrastructure for psychedelics research and clinical delivery that is free of hype and bias. Sisti advises moving ahead with caution, while noting that “the range of potentially treatable conditions is wide—including PTSD, major depression, anxiety disorder, obsessive compulsive disorder, anorexia nervosa, and substance use disorders.” The guest editorial is published in the January-February 2025 issue of JCP.

In this episode of the SMFM Podcast, Dr. Alireza Shamshirsaz welcomes Dr. Bill Grobman, Editor-in-Chief of SMFM's first official journal, Pregnancy. Together, they explore the vision behind this new Open Access journal, its mission to increase accessibility and transparency of original research in obstetrics, and the global and diverse representation it aims to achieve. Dr. Grobman shares his passion for advancing research on pregnancy in its broadest context, touching on topics such as equitable outcomes, the life-course impact of pregnancy, and socio-political dimensions. Listeners will learn about the journal's format, submission guidelines, and opportunities for involvement, including serving as a reviewer or joining the editorial board. Discover how Pregnancy aims to serve as a platform for groundbreaking research and collaboration, fostering meaningful contributions to the field of maternal-fetal medicine. Click here for the full transcript.  Additional Resources:  Learn more about the new journal by visiting smfm.org/pregnancy

Editor in Chief Dr. Sue Yom and Associate Editor Dr. Neil Taunk, Assistant Professor of Radiation Oncology and Chief of the Gynecologic Radiation Service at the University of Pennsylvania, co-host a podcast on "Biomarker expression and impact on clinical outcomes in an international study of chemoradiation and MRI-based image-guided brachytherapy for locally advanced cervical cancer: BIOEMBRACE," with guests Dr. Supriya Chopra, Professor at Tata Memorial Centre in Mumbai, India, and Dr. Remi Nout, Professor and Head of the Department of Radiotherapy of the Erasmus Medical Center, University Medical Center, in Rotterdam, Netherlands, who were the first and last authors and both principal investigators of the BIOEMBRACE study.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Francesco Fanfani to discuss secondary cytoreductive surgery in endometrial cancer. Dr. Francesco Fanfani serves as an associate professor in gynecologic oncology at Fondazione Policlinico Universitario Agostino Gemelli, IRCCS in Rome, Italy. Highlights: Secondary cytoreductive surgery with complete gross resection, has the potential to offer significant survival benefits in recurrent endometrial cancer patients. Age

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Domenica Lorusso to discuss  KEYNOTE-A18 Overall Survival Results: Pembrolizumab and Chemoradiotherapy. Dr. Domenica Lorusso, MD, PhD, directs the Gynaecological Oncology Unit at Humanitas Hospital, Milan, and holds a Full Professorship in Obstetrics and Gynaecology at Humanitas University, Rozzano, Milan. She has led/participated in approximately 250 phase I-IV clinical trials. Currently overseeing more than 60 studies as Principal Investigator, Dr. Lorusso also chairs the Clinical Trials Committee of the MITO Group. She serves on the Board of Directors of the GCIG and is an active member of ENGOT, where she chairs the Gynecological Cancer Academy. Additionally, she sits on the Board of Directors of the ESGO. With around 300 international oncology publications and contributions to national and international treatment guidelines, her primary objectives are to ensure optimal patient care, foster clinical research, and advance international collaborations and education in the field. Highlights:  In a phase 3 trial (ENGOT-cx11/GOG-3047/KEYNOTE-A18), pembrolizumab added to chemoradiotherapy significantly improved progression-free survival and overall survival for patients with locally advanced, high-risk cervical cancer. Patient Group: 1060 patients with FIGO 2014 stage IB2–IVA cervical cancer from 30 countries were randomized to receive pembrolizumab with chemoradiotherapy or placebo with chemoradiotherapy. Overall Survival: At a median follow-up of 29.9 months, the 36-month overall survival rate was 82.6% in the pembrolizumab group versus 74.8% in the placebo group, with a hazard ratio for death of 0.67 (95% CI 0.50–0.90; p=0.0040). Safety Profile: Grade 3 or higher adverse events were reported in 78% of pembrolizumab-treated patients versus 70% in the placebo group, with higher rates of potentially immune-mediated adverse events in the pembrolizumab group (39% vs. 17%). Conclusion: These findings confirm pembrolizumab plus chemoradiotherapy as an effective and potentially new standard of care for locally advanced cervical cancer.

Editor-in-Chief Dr. Sue Yom hosts Dr. Mai Anh Huynh, Assistant Professor of Radiation Oncology at the Brigham and Women's Hospital / Dana-Farber Cancer Center who wrote an editorial this month, "The Hidden Benefits of Palliative Radiotherapy: When Radiation of Metastatic Disease is Not "Just" Palliative," Dr. David Palma, a Radiation Oncologist at the London Health Sciences Centre who co-authored, "Ablative Radiation Therapy to Restrain Everything Safely Treatable (ARREST): A Phase I Study of Stereotactic Ablative Radiotherapy for Poly-metastatic Disease", and Dr. Ethan Ludmir, Assistant Professor in the Departments of Gastrointestinal Radiation Oncology and Biostatistics at the University of Texas MD Anderson Cancer Center and supervising author of "Off-Protocol Radiotherapy in Phase III Metastatic Solid Tumor Trials." The group also discusses an article from this month's issue, "Is Local Ablative Stereotactic Radiation Therapy a Valuable Rescue Strategy for Time on Drug in Patients Enrolled in Phase I Trials?"

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Alessandro Santin to discuss Sacituzumab Govitecan (TROPiCS—03) in Advanced Endometrial Cancer. Dr. Alessandro D. Santin, a native of Italy, graduated with honors from the University of Brescia, Italy and received his postgraduate training in Obstetrics & Gynecology at the same University. He served a fellowship in Gynecologic Oncology at the University of California, Irvine and an International Fellowship in the Division of Gynecologic Oncology at the University of Arkansas for Medical Sciences, Little Rock, Arkansas. Dr. Santin joined the faculty in the Section of Gynecologic Oncology in the Department of Obstetrics, Gynecology & Reproductive Sciences at Yale University as Professor as of July 2008. Dr. Santin has more than 400 original research and peer-reviewed publications including multiple review articles and book chapters and he has written extensively on various topics, including cancer of the ovary, endometrium and cervix as well as on tumor immunology and immunotherapy. Dr. Santin's clinical interests include the use of immunotherapy in ovarian, cervical and endometrial carcinoma patients with disease resistant/refractory to standard treatment, therapeutic vaccines against Human Papillomavirus (HPV) infected genital tumors, and the development of personalized treatment modalities including monoclonal antibodies and antibody-drug-conjugates (ADC) against chemotherapy resistant gynecologic tumors. Highlights: In the TROPiCS-03 trial Sacituzumab Govitecan demonstrated encouraging clinical activity in recurrent endometrial cancer patients in progression after chemotherapy and immune check point inhibitors Sacituzumab Govitecan toxicity profile was manageable with only 5% of patients discontinuing treatment due to TRAEs TROP-2 protein was expressed in over 90% of endometrial cancer patients enrolled in the TROPiCS-03 trial and showed limited correlation with efficacy to Sacituzumab Govitecan

Episode: November/December Issue on Controversies in PALTC with Special Guest Joanne Kaldy Host: Karl Steinberg, MD, HMDC, CMD (Editor Emeritus) Guest(s): Joanne Kaldy (Senior Contributing Writer); Elizabeth Galik, PhD, CRNP (Editor-in-Chief) In This Episode: In this episode, host Dr. Karl Steinberg, MD, CMD, and editor-in-chief Dr. Elizabeth Galik, PhD, CRNP, discuss our November-December issue of Caring for the Ages with our senior contributing writer Joanne Kaldy. Not only does this podcast cover our Special Section on Controversies in post-acute and long-term care, it is also our 25th anniversary! Ms. Kaldy has been with Caring since the beginning, and joins to reminisce with Dr. Steinberg (Caring's editor emeritus) about Caring's journey from 1999 to today. Additionally, Ms. Kaldy wrote this month's cover story on direct-to-consumer marketing, and what to do when a patient asks for a drug by name. Dr. Galik also discusses an article about when it's appropriate to prescribe anticonvulsants, and her own article questioning whether or not dementia special care facilities/units are successful. Don't miss this very exciting 25th anniversary podcast! Featured Articles: When a Patient or Caregiver Asks for a Drug by Name, What Should Practitioners Do? Controversies in Aging: Anticonvulsants for Management of Agitation in Dementia What Is Special About Dementia Special Care? We're Celebrating Our 25th Anniversary! Date Recorded: October 29, 2024 Available Credit: The American Board of Post-Acute and Long-Term Care Medicine (ABPLM) issues CMD credits for select PALTtalk podcast episodes as follows: Claim CMD Credit

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Drs. Drs. Anne Knisely and Nitecki Wilke to discuss Racial and Sociodemographic Disparities with Novel Therapeutics. Dr. Knisely is a 3rd year gynecologic oncology fellow at MD Anderson Cancer Center. She is originally from the New York City area and completed her residency training in Ob/Gyn at Columbia University in 2022 where Dr. Jason Wright served as her primary research mentor. Her current research focuses on early phase clinical trials, minimal residual disease in ovarian cancer, and sociodemographic factors that affect oncologic treatment and outcomes. She is a current SGO/GOG-F BRIDGES Research Scholar. In her free time, she mostly chases around her two toddlers, Zoe (3.5) and Isaiah (2). Dr. Nitecki Wilke is a gynecologic oncologist and assistant professor at the department of gynecologic oncology and reproductive medicine at the University of Texas MD Anderson Cancer Center.   Highlights: Of the 6242 patients who met inclusion criteria and were included in the final cohort, 4.4% received a PARP inhibitor, 34% received bevacizumab, and 6% received both.  On multivariable analysis, non-Hispanic Black patients were 23% less likely than non-Hispanic white patients to receive either targeted therapy Most patients in the study were treated in the recurrent setting; we suspect that the potential barriers to guideline-concordant prescription of these therapeutics would persist in the upfront treatment setting, but future studies are required to validate this. A key area of focus to reduce disparities in access to targeted therapies should be ensuring adequate reimbursement for genetic/ biomarker testing as well as brainstorming creative solutions to expand access to genetic counseling, including the use of mainstreaming. Use of the SEER-Medicare database specifically reduces external validity of this study, but the results are nonetheless hypothesis generating and should spark conversation regarding potential inequitable receipt of PARP inhibitors and bevacizumab in advanced ovarian cancer

December 2024 will mark 22 years since the launch of the Africanist Press. The Africanist Press was established by journalists and academics in December 2002 as an independent media organization to defend free speech, expose corruption, and promote democracy and development in Africa. In 22 years, Africanist Press has grown into a robust media organization known internationally for its groundbreaking investigative journalism exposing corruption, human rights violations, and multinational exploitation. In this episode, editor-in-chief Dr. Chernoh Alpha Bah discusses the enduring impact of the Africanist Press, and the planned expansion and official launch of a new Africanist Press multimedia initiative in December 2024 to commemorate the 22nd anniversary of the organization.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Drs. Rongyu Zang and Yulian Chen to discuss the SOC-1 trial. Dr. Rongyu Zang is the Director of the Department of Gynecologic Oncology, Fudan University Zhongshan Hospital, & Institute for Ovarian Cancer, Fudan University and is the Principal investigator of the SOC-1 and SUNNY trials. Dr. Yulian Chen is an Attending Physician at the Department of Gynecologic Oncology, Fudan University Zhongshan Hospital.   Highlights: The SOC-1 trial concluded that in patients with platinum-sensitive, relapsed ovarian cancer, surgery did not increase overall survival in the intention-to-treat population, but resulted in a prolongation of survival after adjustment of crossover. Surgery may provide an obviously higher proportion of long-term relapse-free survivors than chemotherapy alone. An active preoperative evaluation for all patients with platinum-sensitive first relapsed ovarian cancer is suggested in specialized centers.

Episode: October 2024, with Special Guest Dr. Kate Galluzzi on Utilization of Telemedicine to Supervise Medical Students in the PALTC Setting Host: Karl Steinberg, MD, HMDC, CMD Guest(s): Katherine E. Galluzzi, DO, CMD, FACOFP *dist.*; Barbara Resnick, PhD, CRNP (Co-Editor-in-Chief, JAMDA) In This Episode: In this episode, host Dr. Karl Steinberg, MD, CMD, and co-editor-in-chief Dr. Barb Resnick, PhD, CRNP, will talk with Dr. Galluzzi about her focus on utilization of telemedicine to supervise medical students in the post-acute and long-term care setting. In addition to Dr. Galluzzi's paper, Drs. Steinberg and Resnick will review three additional articles.  Articles Referenced: Utilization of Telemedicine to Supervise Medical Students in the Post-Acute/Long-Term Care Setting Understanding the Perspectives of Key Stakeholders toward Medicare's Home Health Value-Based Purchasing (HHVBP) in the US Paramedic-Assisted Community Evaluation After Discharge: The PACED Intervention A Cluster Randomized Trial: Mixed Methods Comparison of 2 Approaches to Promote Nonpharmacologic, Resident-Centered Dementia Care in Nursing Homes Date Recorded: October 21, 2024 Available Credit: The American Board of Post-Acute and Long-Term Care Medicine (ABPLM) issues CMD credits for select PALTtalk podcast episodes as follows: Claim CMD Credit

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Drs. Andreas Obermair and Rachel Collings to discuss the impact of surgical complications on surgeons. Dr Obermair is an Australian-based gynaecological oncologist, researcher and leader of innovation. He is the PI of numerous investigator-initiated clinical trials and is never tired of finding more effective and less harmful ways to treat patients diagnosed with gynaecological cancer. Dr Rachel Collings is a gynaecologist and fertility specialist working in private practice in Toowoomba, Australia. She has a particular interest gynaecological surgery and doctor wellbeing.    Highlights: While patients are primarily affected by complications, surgeons are second victims when complications develop. Second victim refers to a clinician who experiences emotional trauma when complications develop. Second victims may feel shame, guilt, sadness and a crisis of confidence. In addition, second victims may develop problems with sleep, or develop musculoskeletal and gastrointestinal symptoms. Second victim syndrome is more likely if complications are severe, caused by a perceived mistake, or if the surgeon is concerned that it may attract criticism from colleagues. 89% of respondents reported having impacts on their sleep when they are involved in a surgical complication. Younger age, fewer years in practice, and female respondents had higher impacts of stress related to complications. Female surgeons reported higher levels of physical and mental health impacts and higher levels of impact on sleep compared with male surgeons.  

Episode: October Issue with Special Guest Melissa McClean on a Geriatric Workforce Enhancement Program Host: Karl Steinberg, MD, HMDC, CMD Guest(s): Elizabeth Galik, PhD, CRNP (editor-in-chief); Melissa McClean, MSN, CRNP, ANP-BC, ACHPN In This Episode: In this episode, host Dr. Karl Steinberg, MD, CMD, and editor-in-chief Dr. Elizabeth Galik, PhD, CRNP, discuss our October issue of Caring for the Ages with guest Melissa McClean, MSN, CRNP, ANP-BC, ACHPN. Ms. McClean talks about a geriatric workforce enhancement program at the University of Maryland with baccalaureate nursing students. Drs. Galik and Steinberg also discuss our cover stories on antibiotic resistance in nursing homes and an upcoming new antibiotic in the urinary tract infection treatment tool kit, as well as an article about utilizing music with dementia patients. Featured Articles: Bolstering the Nursing Home Workforce through Geriatric Workforce Enhancement Programs, by Melissa McClean  Antibiotic Resistance in Nursing Homes: A Reflection of the Global Crisis, by Glenn Tillotson and Angela Donald Pivmecillinam (Pivya): An Upcoming New Antibiotic in the Urinary Tract Infection Tool Kit, by Jessica Zering When Words Fail, Music Speaks, by Elizabeth Galik Date Recorded: October 3, 2024 Available Credit: The American Board of Post-Acute and Long-Term Care Medicine (ABPLM) issues CMD credits for select PALTtalk podcast episodes as follows: Claim CMD Credit

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Ignace Vergote to discuss Tisotumab Vidotin in Second- & Third-Line Recurrent Cervical Cancer. Prof. Vergote was Chairman of the Department of Gynaecology and Obstetrics at the Catholic University Leuven from 2003-2020. He published more than 1050 papers on gynecologic cancer in peer-reviewed journals, and his work was cited more than 90,000 times. He served as President of IGCS, ESGO, EORTC-GCG and ENGOT.   Highlights: Patients with recurrent cervical cancer with progression after platinum/paclitaxel, combined if possible with bevacizumab and anti-PD-(L)1 therapy, have a dismal prognosis The antibody-drug -conjugate tisotumab vedotin showed a statistically significant and clinically meaningful improvement in overall survival, demonstrating a 30% reduction in the risk of death compared with standard of care chemotherapy Consistent benefit in progression-free survival and confirmed response were also observed and supportive of the observed overall survival benefit with tisotumab vedotin The safety profile of tisotumab vedotin was manageable and tolerable, and consistent with previous experience Based on these data, tisotumab vedotin should be considered a potential new standard of care for patients with recurrent cervical cancer who have progressed after first-line systemic therapy

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Luis Chiva to discuss the Elikia project in the Democratic Republic of the Congo. Dr. Luis Chiva is the Head of Gynecology and Obstetrics and Director of Gynecologic Oncology at at Clínica Universidad de Navarra.   Highlights: Inspiration: Dr. Luis Chiva began the Elikia project in the DRC in 2016 after seeing the urgent need for cervical cancer screening and maternal health. Screening Approach: The project uses visual inspection with acetic acid, inspired by a successful model from India, to reduce cervical cancer mortality. Team and Challenges: A team of volunteers faces challenges like limited healthcare infrastructure and promoting preventive care. Sustainability: The project relies on donations and grants  to remain sustainable. Personal Impact: The work has profoundly influenced Dr. Chiva, renewing his commitment to humanitarian efforts.

Editor in Chief Dr. Sue Yom co-hosts with Dr. Nicholas Zaorsky, an Associate Editor at the Journal and Associate Professor in the Department of Radiation Oncology at Case Western University Hospitals. We discuss three articles that are publishing rapid online for this meeting including Bladder Adjuvant RadioTherapy (BART): Acute and Late Toxicity from a Phase III Multicenter Randomized Controlled Trial, with the Principal Investigator Dr. Vedang Murthy, Professor in the Department of Radiation Oncology at Tata Memorial Centre in Mumbai, and its accompanying editorial, Adjuvant Radiation Therapy for Locally Advanced Bladder Cancer: A Safe and Promising  Emerging Treatment Option, with first author Dr. Brian Baumann, Radiation Oncologist at Springfield Clinic in Illinois. Relevant to this discussion is a paper appearing in this month's issue, The Value and Safety of Adjuvant Radiation Therapy After Radical Cystectomy in Locally Advanced Urothelial Bladder Cancer: A Controlled Randomized Study and its accompanying editorial, Is It Time to Reconsider the Place of Adjuvant Radiation Therapy After Radical Cystectomy? Finally, our third rapid online paper is Setting the Stage: Feasibility and Baseline Characteristics in the Prostate Advanced Radiation Technologies Investigating Quality of Life (PARTIQoL) Trial Comparing Proton Therapy vs. IMRT for Localized Prostate Cancer, with Principal Investigator Dr. Jason Efstathiou, Professor of Radiation Oncology at Harvard Medical School, Massachusetts General Hospital.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Anuja Jhingran to discuss the role of chemotherapy following chemoradiation after radical hysterectomy. Dr. Anuja Jhingran is a Professor of Radiation Oncology specializing in gynecologic cancers. Her clinical focus includes advanced ovarian, cervical, and endometrial cancers, utilizing advanced radiation techniques to reduce toxicity. Dr. Jhingran is actively involved in research with the Radiation Therapy Oncology Group (RTOG) and Gynecologic Oncology Group (GOG), serving as the national Principal Investigator for several studies. She is passionate about women's health and works internationally to improve healthcare in developing countries.   Highlights: This study assessed the impact of adding adjuvant chemotherapy to chemoradiotherapy (CRT) in patients with high-risk early-stage cervical cancer post-radical hysterectomy.  A total of 212 patients were analyzed, with 109 receiving CRT alone and 103 receiving CRT plus chemotherapy.  The 4-year disease-free survival (DFS) was 76% for the CRT group and 77% for the CRT plus chemotherapy group (HR = 1.05, 90% CI: 0.65-1.68, p = 0.56).  Overall survival (OS) rates at 4 years were 87% for CRT and 89% for the CRT plus chemotherapy arm (HR = 0.91, 90% CI: 0.49-1.69, p = 0.40).  The addition of chemotherapy did not significantly improve DFS or OS.  

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Gregg Nelson to discuss ERAS Guidelines and Outcomes Meta-analysis. Dr. Gregg Nelson is Professor and Chair of Gynecologic Oncology at the University of Calgary, in Calgary, Canada. He is the Physician Lead for ERAS Alberta and is Co-Chair of Enhanced Recovery Canada.  Highlights: Largest meta-analysis of ERAS randomized clinical trials finds hospital length of stay decreased by 1.9 days overall and risk of complications decreased by 29%, in favor of ERAS ERAS can be applied to both open and minimally invasive surgery ERAS benefits multiple surgery types

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Drs. Timo Westermann and Philipp Harter to discuss fertility-sparing surgery in borderline ovarian tumors. Dr. Timo Westermann is a gynecologist and fellow at the Department of Gynecologic Oncology at Kliniken Essen-Mitte. Dr. Philipp Harter is a gynecologic oncologist, working at Kliniken Essen Mitte and Chair of the AGO Study Group.   Highlights:   Fertility-Sparing Surgery in Borderline-Tumors does not negatively impact overall survival. Higher recurrence rates are observed after fertility-sparing surgery, particularly in higher FIGO stages. Long-term follow up is crucial due to potential risk of late recurrences.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Enrique Chacón to discuss the SENECA Study: Molecular profiling and SLN. Dr. Chacón works in the Gynecologic Oncology Unit of the Clínica Universidad de Navarra. Dr. Chacón is an active member of the European Society of Gynecologic Oncology where he is the co-chair of the ENYGO Online Education Committee and the national representative of Spain. In 2021 he completed his editorial fellowship in the IJGC, where today he is serving on the Editorial Board of the journal.   Highlights:   This study, for the first time, reveals significant differences in SLN involvement among more than 2000 patients with early-stage endometrial cancer based on their molecular subtypes, with the p53 abn and MMRd groups having the greatest lymph node involvement. The study defined the risk of SLN involvement for each of the ESGO risk groups. In this sense, the study notes that molecular profiling does not improve the prediction of nodal status with respect to the classical risk factors (FIGO stage and histology). Lymph node staging should not yet be adopted based on molecular profiling as prospective studies are needed to validate whether these differences impact survival (DFS/OS)

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Drs. Lot Aronson and Willemien van Driel to discuss OVHIPEC1 overall survival analysis. Dr. van Driel is a gynecological oncologist at the Netherlands Cancer Institute since 2004 and has, amongst others, a special interest in determining the role of HIPEC in the treatment of patients with advanced ovarian carcinoma and is PI of the OVHIPEC 1 and OVHIPEC 2 study. Dr. Aronson is a medical doctor currently pursuing a PhD in Gynaecological Oncology at the Netherlands Cancer Institute in Amsterdam. Her research focuses on hyperthermic intraperitoneal chemotherapy (HIPEC) as well as immunotherapy in primary advanced ovarian cancer.    Highlights: The long-term survival analysis of the OVIHPEC-1 study confirms the significant improvement in progression-free and overall survival when adding HIPEC to interval cytoreductive surgery in patients with FIGO stage III ovarian carcinoma for whom primary cytoreduction is not considered feasible due to extensive disease. Neither the number of lines nor the type of subsequent treatment for recurrence differed between the treatment groups. Therefore, the observed improvement in overall survival is unlikely to be attributable a difference in subsequent therapies. Identification of biomarkers (e.g. BRCA/HRD status) to select patients for HIPEC and the combination of HIPEC with PARP inhibitors warrants further investigation.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Mary McCormack to discuss the INTERLACE trial. Dr. McCormack is an Honorary Consultant Clinical Oncologist at University College London Hospitals NHS Trust and an Honorary Associate Clinical Professor at University College London.   Highlights: • INTERLACE first randomised PH3 trial in Locally advanced cervical cancer in more than 2 decades to demonstrate a clinically meaningful and statistically significant improvement in both OS and PFS . • The IC drugs are widely available and relatively cheap so removing many potential economic barriers to adoption. • Growth factors -GCSF/Filgrastim should be used as needed to ensure patients complete the chemotherapy (IC & cisplatin) • Essential to BEGIN the external beam radiation within 7 days of last dose ( #6) of IC. • Remember OVERALL treatment time for the RADIATION- 96% in trial completed both EXTERNAL BEAM & BRACHYTHERAPY within 56 days.

Episode: August/September 2024 Host: Karl Steinberg, MD, HMDC, CMD Guest(s): Christopher Laxton; Elizabeth Galik, PhD, CRNP (editor-in-chief) In This Episode: In this episode, host Dr. Karl Steinberg, MD, CMD, and editor-in-chief Dr. Elizabeth Galik, PhD, CRNP, discuss our August/September issue of Caring for the Ages with guest Chris Laxton. This issue contains a special section on Alternative Communities of Care, including medical foster homes for veterans, caring for dementia patients at home, and cohousing communities. Chris Laxton, the former executive director of PALTmed (formerly called AMDA - The Society for Post-Acute and Long-Term Care) joins to talk about his own experience with intergenerational living with his daughter's family. Featured Articles: Medical Foster Home: A Model to Support Aging in Place and Develop Community for Older Adults  My Experience With Multigenerational Living  Tips and Resources for Home-Based Dementia Care If Community Matters to You, Cohousing May Be a Great Way to Age in Place Date Recorded: August 2, 2024 Available Credit: The American Board of Post-Acute and Long-Term Care Medicine (ABPLM) issues CMD credits for select PALTtalk podcast episodes as follows: Claim CMD Credit

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Andrea Rosati. Mr. Rosati is a consultant at the Department of Gynecologic Oncology at Fondazione Policlinico Universitario Agostino Gemelli in Rome (Italy). He is currently attending a second level master "Gynecologic Oncology International Master" at the Catholic University of the Sacred Heart (Rome, Italy) accredited as a Subspecialty Fellowship by the European Society of Gynaecological Oncology. His main interest areas are gynecological cancer, surgical anatomy, and gynecologic oncology surgery.   Highlights: This study evaluated the prevalence of concurrent endometrial cancer in patients with pre-operative diagnoses of atypical endometrial hyperplasia undergoing hysterectomy.  Among 460 patients, 47.2% were found to have concurrent endometrial cancer. Sentinel lymph node biopsy provided prognostic and therapeutic information in 60.8% of cases.  It also allowed for the adjustment of adjuvant therapy in 12.3% of high to intermediate-risk patients without increasing operative time or complication rates.  The study suggests sentinel lymph node biopsy can provide valuable prognostic and therapeutic insights in managing atypical endometrial hyperplasia.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Robert Coleman to discuss overall survival of SORAYA trial. Dr. Coleman completed his Obstetrics & Gynecology residency at Northwestern University Medical Center in Chicago, Illinois, and completed his fellowship at The University of Texas MD Anderson Cancer Center in 1993. From 1993-1996, he served as Assistant Professor at Creighton University followed by service as Vice-Chairman, Department of Obstetrics and Gynecology at the University of Texas, Southwestern Medical Center. Dr. Coleman joined as Faculty at MD Anderson Cancer center in 2004 and served as Professor and Executive Director for Cancer Network Research, holding the Ann Rife Cox Chair in Gynecology. In March 2020, he joined US Oncology Research (USOR) as Chief Scientific Officer and served briefly as Chief Medical Officer for Sarah Cannon Research Institute (SCRI). He currently serves as Chief Medical officer for Vaniam Group. Dr. Coleman has authored or coauthored over 750 scientific publications, including over 450 peer-reviewed articles, along with numerous book chapters, monographs, invited articles, and textbooks. He was the 2019 APGO-CREOG awardee for Excellence in Teaching. He serves as Vice President of GOG-Foundation, Inc. He served as President of SGO (2015-2016) and is the immediate Past-President of IGCS. He was recently inducted into MJH Life Sciences™ 2020 class of “Giants in Cancer Care®.”   Highlights: Mirvetuximab soravtansine (MIRV) is a first-in-class antibody-drug conjugate comprising an  FRα-binding antibody, cleavable linker, and maytansinoid DM4, a potent tubulin-targeting agent Early clinical data suggested efficacy in recurrent platinum-resistant ovarian cancer (PROC) prompting a larger trial to confirm both safety and efficacy in patients with PROC In this SORAYA trial MIRV demonstrated clinically meaningful antitumor activity in patients with FRα-high platinum-resistant ovarian cancer with an ORR: 32.4% and a median DOR: 6.9 months Remarkably the median OS was 15 months; 37% patients alive at 24 months Efficacy of MIRV was further evaluated with respect to when it was administered (as first treatment for PROC) and in patients receiving prior bevacizumab.  An ORR of 34.8% was documented in the formers, and 31.5% in the latter. The ocular toxicity was new for many treating physicians when the drug first became available. However with mitigating strategies as used in the study the events were predictable, low-grade, and rarely (n=1 patient) led to treatment discontinuation Now with MIRASOL confirming these data and demonstrating efficacy over standard of care for response, PFS, and unprecedently, OS, the agent is a staple of contemporary management.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Drs. Kirsten Jorgensen and Alex Melamed to discuss fertility sparing surgery in cervical tumors (

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Drs. Mansoor Mirza and Angélica Nogueira Rodrigues to discuss recent updates on endometrial cancer in Latin America. Dr. Mirza is a highly qualified medical oncologist with expertise in Medical and Radiation Oncology, holding multiple degrees and licenses in these fields. He currently serves as the Chief Oncologist at the Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Denmark, and holds the position of Medical Director of the Nordic Society of Gynaecologic Oncology-Clinical Trial Unit (NSGO-CTU). Dr. Mirza is actively involved in numerous medical societies, clinical research, and international trial collaborations, and has contributed significantly to the development of clinical protocols and guidelines for the management of various cancers. Dr. Angélica Nogueira-Rodrigues is the Founder of EVA Group, and President-elect of the Brazilian Society of Medical Oncology. She is also a Researcher and Professor at Federal University, MG, Brazil, and Chair of Gynecology at the Latin America Cooperative Oncology Group (LACOG).   Highlights:   -Detailed epidemiological data on endometrial cancer in Latin America are scant, but GLOBOCAN provides estimates for the incidence of uterine cancer within countries globally. EC is the second gyn cancer in the region, due to the burden of CC which is still the first one. It is estimated that the total number of new cases of uterine cancer in Latin America and the Caribbean will rise from approximately 33,000 in 2020 to an estimated 51,000 in 2040; -The last ten years have been marked by a radical transformation in the understanding of the molecular biology of endometrial cancer, and, including it.  or not  in FIGO staging, this discussion needs to evolve and be incorporated into clinical practice  in Latin America, as it impacts clinical decision, hereditary cancer diagnosis, among others. -The main message for young gynecological oncologists as us to create a future medicine with fewer disparities worldwide is to strive  to get access an implement the best for the patient,  avoiding protocols adapted for low-income countries which can negatively impact the clinical outcomes.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Ann H. Klopp to discuss radiation alone vs chemoradiation in endometrial cancer recurrence. Dr. Ann H. Klopp is a Professor of Radiation Oncology at MD Anderson Cancer Center, the head of the Gynecologic Oncology Section and a physician-scientist specializing in the treatment of gynecologic cancers. Her research focuses on improving outcomes for women with gynecologic cancers by enhancing tumor directed immune response in combination with radiation therapy and using advanced techniques to increase precision of radiation treatment delivery. Highlights: NRG0238 compared chemoradiation to radiation alone for patients with locally recurrent endometrial cancer and found that the addition of chemotherapy did not improve progression-free survival. Radiation therapy is highly effective for treatment for local recurrences of endometrial cancer. The nuances of patients enrolled and treatment delivered are discussed.

Episode: June/Juy 2024 Host: Karl Steinberg, MD, HMDC, CMD Guest(s): Daniel Haimowitz, MD, FACP, CMD; Elizabeth Galik, PhD, CRNP (editor-in-chief) In This Episode: In this episode, host Karl Steinberg, MD, CMD, and editor-in-chief Dr. Elizabeth Galik, PhD, CRNP, discuss our June/July issue of Caring for the Ages with guest Daniel Haimowitz, MD, FACP, CMD. Dr. Haimowitz shares the evidence-based for what to do about falls with minor head impact in older adults. And Dr. Galik talks about our cover story on addressing ageism when it comes to evaluating both political leaders and job candidates, and her own article on the advantages of small assisted living communities. This issue also contains and special section on the PALTC24 conference in San Antonio, TX, with a featured article on reclaiming joy and releasing stress and burnout. Be sure to check out the rest of this important special issue, including articles on artificial intelligence, F-Tag revisions for substance use disorder, antiplatelet and anticoagulation medications, and more! Featured Articles: Reframing Aging in Politics: Evaluating Job Candidates Beyond Chronological Age Heads Up: Considerations for Falls With Minor Head Impact in Long-Term Care "Don't Count the Small Ones Out": Advantages and Opportunities for Small Assisted Living Communities Catch and Release: Reclaim Joy and Release Stress and Burnout Date Recorded: July 1, 2024 Available Credit: The American Board of Post-Acute and Long-Term Care Medicine (ABPLM) issues CMD credits for AMDA On-The-Go and affiliate podcast episodes as follows: Claim CMD Credit

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Christina Uwins to discuss the MIRRORS trial. Christina Uwins is a final year Subspecialty Fellow in Gynaecological Oncology, working together with Mr Simon Butler-Manuel on the MIRRORS study based at Royal Surrey NHS Foundation Trust, Guildford, UK.  Christina has clinical, research and teaching experience and is enthusiastic about continuing her work in Gynaecological Oncology. Highlights: Retrospective studies have suggested that minimally invasive interval debulking surgery is feasible.  There are no prospective trials on robotic interval debulking surgery for advanced ovarian cancer.  MIRRORS is a prospective cohort study assessing the feasibility of robotic interval debulking surgery for advanced-stage ovarian cancer.  MIRRORS demonstrated the feasibility and safety of robotic interval debulking surgery in advanced-stage ovarian cancer. MIRRORS is the first in a series of three planned trials culminating in a multicenter international randomized controlled trial of MIRRORS protocol -versus standard open interval debulking surgery (MIRRORS-RCT).  In the UK and Europe, the majority of patients with advanced ovarian cancer have interval debulking surgery performed through an open approach. If non-inferiority of robotic interval debulking surgery with regards to survival (overall and progression free) is confirmed by an adequately powered randomized controlled trial, this could lead to a significant change in practice.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Dimitrios Nasioudis to discuss lymphadenectomy at the time of interval cytoreduction for ovarian cancer. Dimitrios Nasioudis is a gynecologic oncologist at the University of Pennsylvania. Following medical training at the Aristotle University of Thessaloniki, and a research fellowship at the Weill Cornell Medical College he completed his residency and fellowship training at the Hospital of the University of Pennsylvania. His current area of research is translational therapeutics with a focus on low-grade serous ovarian carcinoma. His research interests also include population science and surgical outcomes research. Highlights: The study aimed to evaluate the role of systematic lymphadenectomy during interval cytoreductive surgery in advanced-stage epithelial ovarian carcinoma patients who achieved complete gross resection. An analysis of data from 1060 patients found that those who underwent systematic lymphadenectomy had higher rates of unplanned readmissions and longer hospital stays, with no significant difference in overall survival. Systematic lymphadenectomy was rarely performed and did not provide a survival benefit for these patients.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Drs. Gabriel Levin and Behrouz Zand to discuss ChatGPT-fabricated abstracts in gynecologic oncology. Dr. Gabriel Levin is a gynecologic oncology Fellow at McGill University, and an assistant professor at the Hebrew University of Jerusalem. His research encompasses population database studies with clinical implication and innovations in medical education and health care. Dr. Behrouz Zand is a gynecologic oncologist at Houston Methodist Hospital's Neal Cancer Center and Department of Obstetrics and Gynecology, and an assistant professor at Weill Cornell College at Houston Methodist Academic Institute. Specializing in innovative cancer care and clinical trials, he is passionate about integrating AI in medicine, a recent alumnus of the physician program at MIT for AI integration in healthcare. Dr. Zand combines cutting-edge research with compassionate patient care to advance the field.   Highlights:   Reviewers had difficulty in discriminating ChatGPT-written abstracts. Reviewers correctly identified only 46.3% of ChatGPT-generated abstracts, with human-written abstracts slightly higher at 53.7%.  Senior reviewers and those familiar with AI had higher correct identification rates, with senior reviewers at 60% and juniors/residents at 45%. Experience and familiarity with AI were independently associated with higher correct identification rates. ChatGPT assists researchers by generating reviews, summaries, and enhancing writing clarity, but it raises ethical concerns and could diminish human expertise. For non-English speaking authors, it improves writing quality and clarity. In scientific writing, it enhances clarity, summarizes concisely, brainstorms ideas, assists with terminology, and offers data interpretation, augmenting human expertise. ChatGPT and AI in scientific writing can lead to ethical issues, factual inaccuracies, and may eventually diminish human expertise and critical thinking.

Episode: June 2024 Host: Karl Steinberg, MD, HMDC, CMD Guest(s): Tess Jones, PhD, MSW; Barbara Resnick, PhD, CRNP (co-editor-in-chief) In This Episode: In this episode, host Dr. Karl Steinberg, MD, CMD, and co-editor-in-chief Dr. Barb Resnick, PhD, CRNP, will talk with Tessa Jones, PhD, MSW, about her work entitled, Race and Ethnicity Are Related to Undesirable Home Health Care Outcomes in Seriously Ill Older Adults. In addition to Dr. Jones's paper, the following articles will be highlighted and reviewed: The Impact of Delirium on Recovery in Geriatric Rehabilitation after Acute Infection, Bridging Hospital and Nursing Home: Collaboration for Smoother Transitions and Reduced Hospitalizations, and Associations between Recreational Screen Time and Brain Health in Middle-Aged and Older Adults: A Large Prospective Cohort Study. Articles Referenced: Race and Ethnicity Are Related to Undesirable Home Health Care Outcomes in Seriously Ill Older Adults The Impact of Delirium on Recovery in Geriatric Rehabilitation after Acute Infection Bridging Hospital and Nursing Home: Collaboration for Smoother Transitions and Reduced Hospitalizations Associations between Recreational Screen Time and Brain Health in Middle-Aged and Older Adults: A Large Prospective Cohort Study Date Recorded: June 14, 2024 Available Credit: The American Board of Post-Acute and Long-Term Care Medicine (ABPLM) issues CMD credits for AMDA On-The-Go and affiliate podcast episodes as follows: Claim CMD Credit

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Domenica Lorusso to discuss the KEYNOTE A18 clinical trial. Dr. Domenica Lorusso, MD, PhD, directs the Gynaecological Oncology Unit at Humanitas Hospital, Milan, and holds a Full Professorship in Obstetrics and Gynaecology at Humanitas University, Rozzano, Milan. She has led/participated in approximately 250 phase I-IV clinical trials. Currently overseeing more than 60 studies as Principal Investigator, Dr. Lorusso also chairs the Clinical Trials Committee of the MITO Group. She serves on the Board of Directors of the GCIG and is an active member of ENGOT, where she chairs the Gynecological Cancer Academy. Additionally, she sits on the Board of Directors of the ESGO. With around 300 international oncology publications and contributions to national and international treatment guidelines, her primary objectives are to ensure optimal patient care, foster clinical research, and advance international collaborations and education in the field.   Highlights: - Concurrent chemoradiation plus brachiterapy represent the standard of care treatment in locally advanced cervical cancer providing up to 70% 5 years OS - Modern radiotherapy technique (IMRT and VMAT) has reported to further increase OS and reduce toxicity  - Immunotherapy has reported to increase OS in advanced or recurrent cervical cancer when compared to standard treatment - Immunotherapy in combination with concurrent high quality chemoradiation in the treatment of locally advanced high risk cervical cancer further increase PFS and OS with respect to standard chemoradiotherapy and should be considered the new standard of care - The combination appears manageable and no substanciad additional toxicity has been reported

Podcast Description: In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Drs. Mueller and Manning-Geist to discuss molecular classification in ovarian preservation for uterine cancer. Jenny Mueller MD is a gynecologic oncologist and an associate attending in the department of surgery at Memorial Sloan Kettering Cancer Center.  She leads the endometrial cancer research team at MSKCC with an emphasis on prospective, translational and collaborative efforts within and across institutions. Beryl Manning-Geist is a Gynecologic surgery fellow at Memorial Sloan Kettering Cancer Center and will be joining Emory University Division of Gynecologic Oncology in 2024 as an assistant professor. Her research focuses on how to leverage the molecular underpinnings of gynecologic cancers for tailored treatment. Highlights: -Patients with microsatellite instability-high/mismatch repair-deficient or copy number-high/TP53abnormal endometrial cancer were at increased risk of concurrent ovarian disease. -The presence of lymphovascular space invasion and positive cytology were also associated with an increased risk of concurrent ovarian disease. -Integrating molecular tumor profiling with pathologic characteristics of disease may help to better risk stratify pre-menopausal patients with endometrial cancer for ovarian preservation.

Podcast Description: In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Drs. Christhardt Köhler and Achim Schneider to discuss radical vaginal trachelectomy. Prof. Christhardt Köhler is a highly accomplished gynecologist and obstetrician specializing in oncological gynecology. He is the Chief Physician of the Department of Gynecology at Asklepios Hospital Altona Hamburg and has won the Briker Award and the Robert B. Hunt Endowed Award. Dr. Kohler is a member of several professional associations, including the German Society for Gynecology and Obstetrics. His expertise is recognized worldwide, and he is listed in the FOCUS top list of physicians for gynecological operations and tumors. He has 1381 scientific publications focusing on spinal muscular atrophy, cervical cancer, and innovative gynecological surgery approaches. Achim Schneider, born on September 17, 1950, in Augsburg, is a distinguished German gynecologist and obstetrician. He earned his doctorate in 1975 and has since made significant contributions to the field, including pioneering new laparoscopic surgical techniques in gynecological oncology in Germany. Schneider held prestigious professorships at the Friedrich Schiller University in Jena and the Charité in Berlin. He has focused on the diagnosis and treatment of genital neoplasms, HPV-associated ano-genital neoplasms, and fertility-preserving surgery for cervical cancer patients. Currently, he heads the dysplasia consultation at the Medical Care Center in Berlin, continuing his impactful work in minimally invasive procedures and cancer prevention. Highlights: Radical vaginal trachelectomy is a fertility-preserving treatment for early cervical cancer, but large studies on its outcomes are lacking. In a study of 471 patients (median age 33), 62% sought pregnancy with a 73% success rate, and 46% experienced pre-term delivery; recurrences occurred in 3.4% of cases, with a 2.1% mortality rate. The study confirms the oncologic safety of the procedure and suggests that high pre-term delivery rates may be due to cervical volume loss, providing a benchmark for future surgical modifications

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Koji Matsuo to discuss new FIGO staging of endometrial cancer. Dr. Matsuo is a clinician-scientist in the area of gynecologic oncology in the United States. His research interest is population-based, heath service outcome research for gynecologic malignancies. Highlights: (1) Survival effect of adjuvant therapy differed between stage IA3 and IIIA1. (2) In new stage IA3 disease, omission of adjuvant therapy had comparable overall survival compared to combination chemotherapy and external beam radiotherapy or chemotherapy alone. (3) In stage IIIA1, omission of adjuvant therapy was associated with decreased overall survival compared to chemotherapy-based approach. (4) 5-year overall survival of adjuvant therapy omission group in new stage IA3 was nearly 90%. (5) These hypothesis-generating observation suggested that treatment de-escalation of well-staged stage IA3 may not adversely affect survival. 

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Shitanshu Uppal to discuss the impact of closure of small fascial bites on incisional hernia rates in gynecologic oncology patients. Dr. Uppal is the George W. Morley Collegiate Professor of Obstetrics and Gynecology and the Division Chief of Gynecologic Oncology at the University of Michigan. Dr. Uppal is recognized for his research in surgical outcomes and quality improvement, alongside his pivotal role in leading educational initiatives for Gynecologic Oncology.   Highlights:   - This quality improvement study validates prior RCT data in gynecologic oncology population - Adoption of Small-Bite Fascial Closure Reduced Hernia rates by 50% - Obesity and adjuvant chemotherapy are independent risk factors for hernia development

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Domenica Lorusso to discuss the survival analysis of the PAOLA1 trial. Dr. Domenica Lorusso, MD, PhD, directs the Gynaecological Oncology Unit at Humanitas Hospital, Milan, and holds a Full Professorship in Obstetrics and Gynaecology at Humanitas University, Rozzano, Milan. She has led/participated in approximately 250 phase I-IV clinical trials. Currently overseeing more than 60 studies as Principal Investigator, Dr. Lorusso also chairs the Clinical Trials Committee of the MITO Group. She serves on the Board of Directors of the GCIG and is an active member of ENGOT, where she chairs the Gynecological Cancer Academy. Additionally, she sits on the Board of Directors of the ESGO. With around 300 international oncology publications and contributions to national and international treatment guidelines, her primary objectives are to ensure optimal patient care, foster clinical research, and advance international collaborations and education in the field.   Highlights: Bevacizumab plus olaparib has reported to increase PFS and OS in advanced stage III-IV, newly diagnosed, high grade serous and endometrioid HRD positive ovarian cancer in the maintenance setting  Exploratory analysis suggest that the advantage is particularly high in low risk patients (stage III withour residual tumor at primary surgery) where  a 5-year OS more  than 90% has been reported suggesting some of these patients may be cured In the HRp population the combination of olaparib-bevacizumab did non increase PFS and OS in comparison to bevacizumab alone The toxicity profile of the combination is in line with what expected with the single drugs

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Ana Luzarraga to discuss molecular profiles as predictors of endometrial recurrence. Dr. Luzarraga is a Gynecologic Oncologist currently working in the Vall d'Hebron University Hospital in Barcelona, Spain. She has completed her two years ESGO fellowship in 2023 and is currently finishing her PhD programme about molecular profile in endometrial cancer.   Highlights: Molecular subgroups of endometrial cancer present distinctive recurrence patterns: p53-abn tumors relapse mostly with peritoneal and distant disease and NSMP tumors at distance. Molecular profile is a stronger independent predictor for vaginal, peritoneal, and distant recurrence than classic histologic factors. P53-abn is the sole independent predictor of peritoneal relapse. P53-abn and NSMP are independent predictors of distant recurrence.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Luis Chiva. Dr. Chiva, Director of Obstetrics and Gynecology at Clinica Universidad de Navarra, is an Honorary Fellow of the American College of Surgeons, a former council member of ESGO, and chaired the Program Committee for ESGO Istanbul 2023. He also serves as Associate Editor for the IJGC.   Highlights: 1. Dr. Luis Chiva's career path in gynecologic oncology stemmed from his father's influence and his own passion for surgery. 2. Training in the United States broadened his perspective, leading him to play a pivotal role in advancing gynecologic oncology in Spain. 3. He emphasized personalized patient care and multidisciplinary approaches to oncology, shaping his leadership in professional societies. 4. Dr. Chiva's journey underscores the importance of continual learning, perseverance, and a strong family support system in achieving professional success. 5. Balancing work and personal life, he believes, is essential for maintaining overall well-being and effectiveness in patient care.

What do we do when the things we are seeing in church or with Christian leaders is leading to disillusionment? How do we deal with the disappointment in the ways Christians behave in the public square, online and in the pews? Author and Editor in Chief Dr. Russell Moore has experienced the pain of denominational turmoil and sharp political disagreements that have led to hurtful slander and unkind discourse. He has found himself at the center of conflicts that he never intended to be a part of. It was through his own personal experiences and the experiences of others that he began to consider the ways in which the American Church was drifting from the heart and purposes of Jesus. In his book, Losing Our Religion: An Altar Call for Evangelical America, Moore explores how the American Church has lost its way and offers an invitation to repentance as a new start forward. In this conversation, Dr. Moore sits down with guest co-host, Eric Schumacher and discusses how to navigate the current cultural unrest as believers, what to do with our disillusionment in the Church, and how to help our friends who are struggling to trust in God based on the behaviors of those claiming to follow Him. If you've struggled with the headlines of fallen leaders and the vitriol of those proclaiming Christ in the midst of current affairs and have been left feeling like the American Church doesn't align with the way of Christ, this episode will give you hope that nothing we are experiencing in this generation is a surprise to Jesus and He is not done yet with His bride.   Website: https://www.russellmoore.com Instagram: https://www.instagram.com/russellmoore Facebook: https://www.facebook.com/russellmoore Twitter: https://www.twitter.com/drmoore Book: Losing Our Religion: An Altar Call for Evangelical America https://a.co/d/cTXM7WA Want to see healing and life transformation after the pain you've encountered? Check out the Pain to Purpose course and start the path towards healing today: https://www.course.nothingiswasted.com Join us for the final 5 Steps Zoom Call of 2023 and start your journey towards healing now: https://www.nothingiswasted.com/starthere Need some hope right now in your valley? Or have a friend who could use some encouragement through suffering? The Pain to Purpose 42-Day Devotional is the perfect companion in your pain. Get your copy and gift one to a friend who needs it: https://www.nothingiswasted.com/store/pain-to-purpose-devotional

Today joining me is my friend Russell Moore. He is RUNNING Christianity Today. I have followed him and what I love about Russell is that he was able to find a lane that a lot of Conservative Christians in America needed him to find.  He speaks to the problems of Christian Nationalism, calls things out when they are not Christ-like and isn't afraid to speak the truth.  He has a podcast called the Russell Moore show and recently launched a new book, Losing My Religion.  I think this conversation will help ALL of us, especially launching into the difficult conversations that are coming in 2024. —-- Listen to Russell's podcast HERE: https://pod.link/1074011166  Purchase his brand new book, Losing My Religion, HERE: https://www.penguinrandomhouse.com/books/709965/losing-our-religion-by-russell-moore/  Follow Russell on Twitter HERE: https://twitter.com/drmoore  Purchase your copy of my new book, How to Human, HERE: https://bit.ly/HowtoHumanNotes Let's keep in touch! Sign up for my newsletter to be the first to hear ALL my updates. https://bit.ly/MasFamiliaNotes Interested in advertising with us? Reach out here. _____ Thanks to our sponsors!  ATHLETIC GREENS: Athletic Greens is giving you a FREE 1-year supply of Vitamin D AND 5 free travel packs with your first purchase. Go to athleticgreens.com/HUMANHOPE. INDEED: Need to hire? You need Indeed. Visit Indeed.com/HUMANHOPE to start hiring now. BETTER HELP: This episode is sponsored by BetterHelp. Give online therapy a try at betterhelp.com/HUMANHOPE and get on your way to being your best self. HIYA HEALTH: Receive 50% off your first order at hiyahealth.com/HUMANHOPE

What do we do when the things we are seeing in church or with Christian leaders is leading to disillusionment? How do we deal with the disappointment in the ways Christians behave in the public square, online and in the pews? Author and Editor in Chief Dr. Russell Moore has experienced the pain of denominational turmoil and sharp political disagreements that have led to hurtful slander and unkind discourse. He has found himself at the center of conflicts that he never intended to be a part of. It was through his own personal experiences and the experiences of others that he began to consider the ways in which the American Church was drifting from the heart and purposes of Jesus. In his book, Losing Our Religion: An Altar Call for Evangelical America, Moore explores how the American Church has lost its way and offers an invitation to repentance as a new start forward. In this conversation, Dr. Moore sits down with guest co-host, Eric Schumacher and discusses how to navigate the current cultural unrest as believers, what to do with our disillusionment in the Church, and how to help our friends who are struggling to trust in God based on the behaviors of those claiming to follow Him. If you've struggled with the headlines of fallen leaders and the vitriol of those proclaiming Christ in the midst of current affairs and have been left feeling like the American Church doesn't align with the way of Christ, this episode will give you hope that nothing we are experiencing in this generation is a surprise to Jesus and He is not done yet with His bride.   Website: www.russellmoore.com Instagram: www.instagram.com/russellmoore Facebook: www.facebook.com/russellmoore Twitter: twitter.com/drmoore Book: Losing Our Religion: An Altar Call for Evangelical America https://a.co/d/cTXM7WA Want to see healing and life transformation after the pain you've encountered? Check out the Pain to Purpose course and start the path towards healing today: www.course.nothingiswasted.com Join us for the final 5 Steps Zoom Call of 2023 and start your journey towards healing now: www.nothingiswasted.com/starthere Need some hope right now in your valley? Or have a friend who could use some encouragement through suffering? The Pain to Purpose 42-Day Devotional is the perfect companion in your pain. Get your copy and gift one to a friend who needs it: www.nothingiswasted.com/store/pain-to-purpose-devotional